Protocol Ledger

NCT03456076 · Phase III · ACTIVE NOT RECRUITING

A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer

Interventional Phase III clinical trial protocol NCT03456076 sponsored by Roche / Genentech in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-08-16 Enrollment: 257 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03456076
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)257 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03456076
Protocol FieldVerified Registry Value
NCT IdentifierNCT03456076
Consolidated Lead SponsorRoche / Genentech
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment257 participants (ACTUAL)
Registered Start Date2018-08-16
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT03456076
Hospital Research SiteLocationSite Profile
Rush University Medical CenterChicago, ILOpen Hospital Dossier ->
Chris O'Brien LifehouseCamperdown, AustraliaOpen Hospital Dossier ->
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Roche / Genentech across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI